Aurinia Pharmaceuticals Newsroom

Earnings Preview: AUPH to Report Financial Results Pre-market on November 07

$Aurinia Pharmaceuticals(AUPH.US)$ is scheduled to release its financial results pre-market on November 07 ET. Earnings PreviewAnalysts estimate $Aurinia Pharmaceuticals(AUPH.US)$ to post revenue of

Futu NewsNov 2 09:00

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024

BusinesswireOct 31 04:05

Even After Rising 5.9% This Past Week, Aurinia Pharmaceuticals (NASDAQ:AUPH) Shareholders Are Still Down 77% Over the Past Three Years

Simply Wall StOct 30 20:12

Axonis Therapeutics Announces $115 Million Series A Financing

PR NewswireOct 30 18:00

Aurinia To Present Six Abstracts, Including Five Poster Presentations, At The American Society Of Nephrology Kidney Week 2024 Taking Place In San Diego, October 23-27

BenzingaOct 11 18:14

Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024

BusinesswireOct 11 18:00

Express News | Aurinia Presents New Data Highlighting Real-World Utilization and Value of Lupkynis® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024

BreakingsOct 11 18:00

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability

Yahoo FinanceSep 27 20:47

Bloom Burton Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $9.4

Futu NewsSep 26 22:31 · Ratings

Aurinia Pharmaceuticals: Strategic Growth and Buy Rating Amidst Japan Market Expansion and M&A Potential

TipRanksSep 26 22:05 · Ratings

Aurinia Announces Japan Approval of LUPKYNIS (Voclosporin) to Treat Lupus Nephritis

BusinesswireSep 24 20:10

Express News | Aurinia Announces Japan Approval of Lupkynis® (Voclosporin) to Treat Lupus Nephritis

BreakingsSep 24 20:10

Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference

BusinesswireSep 13 18:00

Express News | Tang Capital Management Reports 5.1% Stake in Aurinia Pharmaceuticals Inc as of September 6 - SEC Filing

BreakingsSep 13 04:15

Aurinia Pharma: Daniel G. Billen, R. Hector MacKay-Dunn and Brinda Balakrishnan Resigned From Board >AUPH

Dow JonesSep 13 04:12

Aurinia Pharmaceuticals: Kevin Tang, Pres of Tang Capital, Appointed as a Director >AUPH

Dow JonesSep 13 04:09

Aurinia Pharmaceuticals: Peter Greenleaf, Pres and CEO, Remains a Director >AUPH

Dow JonesSep 13 04:08

Express News | Aurinia Announces Board Restructuring

BreakingsSep 13 04:05

Aurinia Pharmaceuticals Price Target Maintained With a $10.00/Share by Cantor Fitzgerald

Dow JonesSep 9 23:27 · Ratings

Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Shares Bounce 30% But Its Business Still Trails The Industry

Simply Wall StSep 6 19:04